The interface is the relationship between allergic foods and an individual’s immune system. During this phase, we identify biosimilar proteins to retrain the immune system and safely build tolerance one protein at a time. Biosimilar proteins are proteins similar to those in a patient’s allergens.
There are 13 protein subgroups that help us study and treat your child’s allergy. Understanding how your child’s system reacts to allergens in the interface helps us make decisions in patient treatment plans. Through the Tolerance Induction Program, patients will never begin by introducing their anaphylactic allergens, but instead build tolerance through dosing biosimilar proteins.
If you are anaphylactic to peanuts, you may be tolerant to hazelnuts, a biosimilar protein.
Through high-dose challenges of similar proteins, foods in the Sensitized column move towards the Tolerant column, making it safer to treat your child’s anaphylactic foods. Through our proprietary gummies, patients can safely and accurately dose at home to condition their system for in-office food challenges.